{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018793","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.715547+00:00","generated_at":"2026-06-02T02:29:40.688838+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ensysce Biosciences reports Q1 net loss of $3.1M; advances PF614 Phase 3 plans","bullets":["Net loss attributable to common stockholders was $3.1M for Q1 2024, vs $2.2M in Q1 2023.","Cash increased to $3.4M at March 31, 2024 from $1.1M at Dec 31, 2023, boosted by $6.8M in warrant exercises.","R&D expenses decreased to $0.8M from $1.8M YoY; G&A decreased to $1.4M from $1.6M.","FDA granted Breakthrough Therapy designation for PF614-MPAR in January; Phase 3 trial for PF614 expected to start H2 2024.","Federal grant revenue fell to $0.3M from $0.8M due to completion of MPAR grant in Dec 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018793","json":"https://secwatch.observer/filing/0001493152-24-018793.json","markdown":"https://secwatch.observer/filing/0001493152-24-018793.md","text":"https://secwatch.observer/filing/0001493152-24-018793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/0001493152-24-018793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:29:40.688838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a46d5c865a5e4634a6cc58e792d4d1e00bad57a3","claim":"Ensysce Biosciences, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million.","evidence_excerpt":"On May 13, 2024, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/0001493152-24-018793-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$3.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}